Provided by Tiger Trade Technology Pte. Ltd.

Finch Therapeutics Group, Inc.

13.49
+0.24001.81%
Volume:400.00
Turnover:5.36K
Market Cap:21.66M
PE:-1.53
High:13.49
Open:13.32
Low:13.32
Close:13.25
52wk High:16.10
52wk Low:11.50
Shares:1.61M
Float Shares:1.12M
Volume Ratio:1.58
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.8239
EPS(LYR):-46.5888
ROE:-67.28%
ROA:-21.89%
PB:1.52
PE(LYR):-0.29

Loading ...

Company Profile

Company Name:
Finch Therapeutics Group, Inc.
Exchange:
PINK LIMITED
Establishment Date:
2014
Employees:
1
Office Location:
75 State Street,Suite 100,Boston,Massachusetts,United States
Zip Code:
02109
Fax:
- -
Introduction:
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.